Overbasalization: Addressing Hesitancy in Treatment Intensification Beyond Basal Insulin.
作者信息
Cowart Kevin
机构信息
Department of Pharmacotherapeutics & Clinical Research, Taneja College of Pharmacy and Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL.
出版信息
Clin Diabetes. 2020 Jul;38(3):304-310. doi: 10.2337/cd19-0061.
Abstract
摘要
相似文献
1
Overbasalization: Addressing Hesitancy in Treatment Intensification Beyond Basal Insulin.
Clin Diabetes. 2020 Jul;38(3):304-310. doi: 10.2337/cd19-0061.
2
Quantifying and Characterizing the Presence of Insulin Overbasalization in a Family Medicine Practice.
Clin Diabetes. 2024 Spring;42(2):266-273. doi: 10.2337/cd23-0044. Epub 2023 Nov 10.
3
Prevalence of and Characteristics Associated With Overbasalization Among Patients With Type 2 Diabetes Using Basal Insulin: A Cross-Sectional Study.
Clin Diabetes. 2021 Apr;39(2):173-175. doi: 10.2337/cd20-0080.
4
Impact of Overbasalization on Clinical Outcomes in Patients With Type 2 Diabetes: A Post Hoc Analysis of a Large Randomized Controlled Trial.
Clin Diabetes. 2023 Spring;41(2):147-153. doi: 10.2337/cd22-0046. Epub 2022 Jul 12.
5
Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care.
Ann Med. 2021 Dec;53(1):998-1009. doi: 10.1080/07853890.2021.1925148.
6
Clinical inertia in basal insulin-treated patients with type 2 diabetes - Results from a retrospective database study in Japan (JDDM 43).
PLoS One. 2018 Sep 18;13(9):e0198160. doi: 10.1371/journal.pone.0198160. eCollection 2018.
7
Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.
J Manag Care Spec Pharm. 2018 Apr;24(4):390-400. doi: 10.18553/jmcp.2017.17218. Epub 2017 Nov 16.
8
What happens when patients require intensification from basal insulin? A retrospective audit of clinical practice for the treatment of type 2 diabetes from four Australian centres.
Diabetes Res Clin Pract. 2015 Jun;108(3):405-13. doi: 10.1016/j.diabres.2015.03.004. Epub 2015 Mar 14.
9
Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
Clin Ther. 2010 May;32(5):896-908. doi: 10.1016/j.clinthera.2010.05.001.
10
Consensus on "Basal insulin in the management of Type 2 Diabetes: Which, When and How?".
J Assoc Physicians India. 2017 Jul;65(7):51-62.
引用本文的文献
1
Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed-ratio basal insulin glucagon-like peptide-1 receptor agonist combinations?
Diabetes Obes Metab. 2025 Aug;27 Suppl 7:3-13. doi: 10.1111/dom.16502. Epub 2025 Jun 11.
2
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025.
Diabetes Care. 2025 Jan 1;48(Supplement_1):S181-S206. doi: 10.2337/dc25-S009.
3
Quantifying and Characterizing the Presence of Insulin Overbasalization in a Family Medicine Practice.
Clin Diabetes. 2024 Spring;42(2):266-273. doi: 10.2337/cd23-0044. Epub 2023 Nov 10.
4
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024.
Diabetes Care. 2024 Jan 1;47(Suppl 1):S158-S178. doi: 10.2337/dc24-S009.
5
The Hypoglycemic Fear Syndrome: Understanding and Addressing This Common Clinical Problem in Adults With Diabetes.
Clin Diabetes. 2023 Fall;41(4):502-509. doi: 10.2337/cd22-0131. Epub 2023 May 25.
6
Simplification of Complex Insulin Regimens with IdegLira in People with Type 2 Diabetes: Literature Review and Clinical Recommendations.
Diabetes Ther. 2023 Nov;14(11):1959-1976. doi: 10.1007/s13300-023-01471-9. Epub 2023 Sep 22.
7
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023.
Diabetes Care. 2023 Jan 1;46(Suppl 1):S140-S157. doi: 10.2337/dc23-S009.
8
Practicable Measurement and Identification of Overbasalization.
Clin Diabetes. 2022 Jan;40(1):75-77. doi: 10.2337/cd21-0096.
9
The Clinical Definition of Overbasalization.
Clin Diabetes. 2021 Oct;39(4):411-414. doi: 10.2337/cd21-0025.
10
Prevalence of and Characteristics Associated With Overbasalization Among Patients With Type 2 Diabetes Using Basal Insulin: A Cross-Sectional Study.
Clin Diabetes. 2021 Apr;39(2):173-175. doi: 10.2337/cd20-0080.
本文引用的文献
1
9. Pharmacologic Approaches to Glycemic Treatment: .
Diabetes Care. 2020 Jan;43(Suppl 1):S98-S110. doi: 10.2337/dc20-S009.
2
6. Glycemic Targets: .
Diabetes Care. 2020 Jan;43(Suppl 1):S66-S76. doi: 10.2337/dc20-S006.
3
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Diabetes Care. 2020 Feb;43(2):487-493. doi: 10.2337/dci19-0066. Epub 2019 Dec 19.
4
Evaluation of the Cascade of Diabetes Care in the United States, 2005-2016.
JAMA Intern Med. 2019 Oct 1;179(10):1376-1385. doi: 10.1001/jamainternmed.2019.2396.
5
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9.
6
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
N Engl J Med. 2019 Aug 29;381(9):841-851. doi: 10.1056/NEJMoa1901118. Epub 2019 Jun 11.
7
Therapeutic Inertia is a Problem for All of Us.
Clin Diabetes. 2019 Apr;37(2):105-106. doi: 10.2337/cd19-0090.
8
Appropriate Titration of Basal Insulin in Type 2 Diabetes and the Potential Role of the Pharmacist.
Adv Ther. 2019 May;36(5):1031-1051. doi: 10.1007/s12325-019-00907-8. Epub 2019 Mar 21.
9
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
Endocr Pract. 2019 Jan;25(1):69-100. doi: 10.4158/CS-2018-0535.
10
When basal insulin is not enough: A dose-response relationship between insulin glargine 100 units/mL and glycaemic control.
Diabetes Obes Metab. 2019 Jun;21(6):1305-1310. doi: 10.1111/dom.13653. Epub 2019 Mar 25.
Zotero 插件